SOLICITATION NOTICE
66 -- G-Rex 100 Gas Permeable Cell Culture Devices
- Notice Date
- 8/31/2011
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110178-MD
- Archive Date
- 9/30/2011
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Cell Production Laboratory plans to procure on a sole source basis the brand name G-Rex 100 Gas Permeable Cell Culture Devices (600 units) from Wilson Wolf Manufacturing Corporation, 33-5th Avenue NW, Suite #700, New Brighton, MN 55112. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 334516 and the business size standard is 500 Employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery expected within three weeks from time of award. The Surgery Branch, National Cancer Institute (SB/NCI) has an ongoing clinical program using adoptive cell transfer therapy for the treatment of patients with metastatic cancer. The cell production laboratory of the SB/NCI uses a number of techniques to identify, purify and expand tumor reactive T lymphocytes from patients with advanced cancer. For adoptive transfer protocols only equipment and protocols that meet the good manufacturing practices (GMP) can be utilized to manufacture patient cells, as mandated by the FDA. SB/NCI requires a series of gas permeable flasks to expand patient cells for adoptive cell therapy. These flasks are critical for the successful expansion of patient cells, to high densities, under static conditions, while providing enhanced aeration. Static culture conditions are essential for the early stages of lymphocyte expansions, where uninterrupted contact with feeders' cells is necessary to provide the essential co-stimulatory signals to initiate a successful patient treatment. The NCI plans to use these gas permeable flasks to expand patient cells for the following clinical protocols and all subsequent protocols (07-C-0176, 08-C-0055, 08-C-0056, 08-C-0121, 09-C-0082, 10-C-0117, 10-C-0166, 11-C-0011 and 11-C-00113). These protocols require the rapid expansion of patients' cells in as small a volume of media as possible in order to facilitate harvesting and washing of the cell product. The required flasks shall be gamma irradiated, single unit gas-culture-permeable devices with a 100 cm2 culture area, a 500 ml medium capacity, and capable of holding 1 billion cells. The required flask size is 4.5" diameter by 4" high as required by the SB/NCI incubator. Wilson Wolf Manufacturing are the sole known suppliers of G-Rex100 flasks, no other known product is available that allows the concentrated growth of patient lymphocytes in a static culture device and fulfills the necessary size and characteristics requirements. This proprietary line of Gas Permeable tissue culture flasks are required for expanding tumor infiltrating lymphocytes and genetically modified PBL to treat patients with advanced metastatic cancer and will support ongoing protocols within the Surgery Branch of the National Cancer Institute. As the product is proprietary, Wilson Wolf Manufacturing is the only known source. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 15, 2011. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110178-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110178-MD/listing.html)
- Record
- SN02556940-W 20110902/110831235426-c55dc80a00246073ac29113fcdf54f2b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |